Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 971 to 980 of 1535 total matches.
In Brief: OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
Drugs Ther 2021; 63:57.
The Medical Letter ® Vol. 64 (1662) October 31, 2022 allergic rhinitis ...
The 0.15% nasal spray formulation of the H1-
antihistamine azelastine hydrochloride (Astepro
Allergy; Children's Astepro Allergy – Bayer) is now
available over the counter (OTC) for temporary relief
of nasal congestion, runny nose, sneezing, and itchy
nose due to allergic rhinitis in adults and children
≥6 years old. It is the first intranasal antihistamine
to be approved by the FDA for OTC use. Other drugs
that are available OTC for treatment of allergic rhinitis
symptoms include oral antihistamines, intranasal
corticosteroids, and mast cell stabilizers.
Ophthalmic Phentolamine (Ryzumvi) for Drug-Induced Mydriasis
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
® Vol. 66 (1705) June 24, 2024
101
1. RS Chuck et al. Comprehensive adult medical eye
evaluation ...
The FDA has approved a 0.75% ophthalmic solution
of the alpha-adrenergic antagonist phentolamine
(Ryzumvi – Viatris) for treatment of mydriasis produced
by adrenergic agonists such as phenylephrine
or parasympatholytic agents such as tropicamide in
patients ≥3 years old. Ryzumvi is the first drug to be
approved in the US for reversal of pharmacologically
induced mydriasis.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):100-1 doi:10.58347/tml.2024.1705c | Show Introduction Hide Introduction
Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
after the
last dose.
The Medical Letter ® Vol. 66 Published online November 11, 2024
DOSAGE ...
Inavolisib (Itovebi – Genentech), an oral kinase
inhibitor, has been approved by the FDA for use in
combination with palbociclib and fulvestrant for
treatment of endocrine-resistant, PIK3CA-mutated,
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer. This is the first
approval for Itovebi; palbociclib and fulvestrant have
been available for years for treatment of HR-positive,
HER2-negative breast cancer.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e186-7 doi:10.58347/tml.2024.1715f | Show Introduction Hide Introduction
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
to another
4
The Medical Letter ® Vol. 57 (1459) January 5, 2015
Table 2. Oritavancin Clinical Trials ...
The FDA has approved oritavancin (Orbactiv – The
Medicines Company), a long-acting lipoglycopeptide
antibiotic given as a single intravenous (IV) dose, for
treatment of acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria in adults. It is the third lipoglycopeptide
antibiotic to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
, and arthralgia. Systemic
adverse effects of inhaled beta2-agonists are generally
2
The Medical Letter ® Vol ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the...
Liraglutide (Saxenda) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
during pregnancy because weight loss is not
90
The Medical Letter ® Vol. 57 (1471) June 22, 2015 ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight management
in adults with a BMI ≥30, or a BMI ≥27 with a
weight-related comorbidity such as hypertension,
dyslipidemia, or diabetes.
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
or to smooth withdrawal later in
the day.
102
The Medical Letter ® Vol. 57 (1473) July 20, 2015
ADVERSE ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
The Medical Letter ® Vol. 57 (1473) July 20, 2015
decreased if it is administered with drugs ...
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase inhibitor, for treatment of
moderate to severe Alzheimer's type dementia in
patients previously stabilized on both drugs. The
patent for Namenda has recently expired and generic
formulations of memantine 5- and 10-mg tablets have
been approved.
Alirocumab (Praluent) to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
.,
atorvastatin 40-80 mg), which generally results in
114
The Medical Letter ® Vol. 57 (1475) August 17, 2015 ...
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional lowering
of LDL-cholesterol (LDL-C). It was not approved for
general use in statin-intolerant patients. Alirocumab
is the first PCSK9 inhibitor to be approved in the US.
Evolocumab (Repatha – Amgen), another PCSK9
inhibitor, was...
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
in trial
2). Responses were maintained for 52 weeks.
162
The Medical Letter ® Vol. 57 (1482) November 23 ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...